Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma

Oncologist

Volumn 20, Issue 5, 2015, Pages 562-567

  Lombardi, Giuseppe ^a   Corona, Giuseppe ^d   Bellu, Luisa ^a   Puppa, Alessandro Della ^e   Pambuku, Ardi ^a   Fiduccia, Pasquale ^b   Bertorelle, Roberta ^c   Gardiman, Marina Paola ^f   D’avella, Domenico ^f   Toffoli, Giuseppe ^d   Zagonel, Vittorina ^a  

^a Medical Oncology 1 ^*  (Italy)

^b Clinical Trials and Biostatistics Unit   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^d CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^e UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

Author keywords

2 Hydroxyglutarate; Biomarker; Glioma; Isocitrate dehydrogenase; Plasma; Urine

Indexed keywords

2 HYDROXYGLUTARIC ACID; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; ALPHA-HYDROXYGLUTARATE; GLUTARIC ACID DERIVATIVE; IDH1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; DIAGNOSTIC VALUE; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GLIOMA; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; TUMOR VOLUME; AGED; BIOSYNTHESIS; BLOOD; CANCER STAGING; GENETICS; MUTATION; URINE;

ADULT; AGED; BIOMARKERS, TUMOR; FEMALE; GLIOMA; GLUTARATES; HUMANS; ISOCITRATE DEHYDROGENASE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS;

EID: 84929080909     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0266     Document Type: Article

References (26)

1. Louis DN, Ohgaki H, Wiestler OD et al. The 2007 WHOclassification of tumours of the central nervous system. Acta Neuropathol 2007;114:97–109.
2. Reitman ZJ, Yan H. Isocitrate dehydrogenase 1 and 2 mutationsincancer:Alterationsatacrossroadsofcellular metabolism. J Natl Cancer Inst 2010;102:932–941.
3. Watanabe T, Nobusawa S, Kleihues P et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009;174:1149–1153.
4. Pusch S, Sahm F, Meyer J et al. Glioma IDH1 mutation patterns off the beaten track. Neuropathol Appl Neurobiol 2011;37:428–430.
5. Dang L, White DW, Gross S et al. Cancerassociated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462:739–744.
6. Frezza C, Tennant DA, Gottlieb E. IDH1 mutations in gliomas: When an enzyme loses its grip. Cancer Cell 2010;17:7–9.
7. Marcucci G, Maharry K, Wu YZ et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 2010;28:2348–2355.
8. Chou WC, Hou HA, Chen CY et al. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood 2010;115:2749–2754.
9. Zou Y, Zeng Y, Zhang DF et al. IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders. Biochem Biophys Res Commun 2010;402:378–383.
10. Gross S, Cairns RA, Minden MD et al. Cancerassociated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2mutations. J Exp Med 2010; 207:339–344.
11. Janin M, Mylonas E, Saada V et al. Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: A study by the Acute Leukemia French Association group. J Clin Oncol 2014;32:297–305.
12. Takahashi N, Boysen G, Li F et al.Tandem mass spectrometry measurements of creatinine inmouse plasma and urine for determining glomerular filtration rate. Kidney Int 2007;71:266–271.
13. Prensner JR, Chinnaiyan AM. Metabolism unhinged: IDH mutations in cancer. Nat Med 2011; 17:291–293.
14. Borger DR, Goyal L, Yau T et al. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. Clin Cancer Res 2014;20:1884–1890.
15. Fathi AT, Sadrzadeh H, Comander AH et al. Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate. The Oncologist 2014;19:602–607.
16. Xu W, Yang H, Liu Y et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of a-ketoglutarate-dependent dioxygenases. Cancer Cell 2011;19:17–30.
17. Capper D, Simon M, Langhans CD et al. 2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlatewith IDH1/2 mutation status or tumor size. Int J Cancer 2012; 131:766–768.
18. Kranendijk M, Struys EA, Salomons GS et al. Progress in understanding 2-hydroxyglutaric acidurias. J Inherit Metab Dis 2012;35:571–587.
19. Hagos Y, Krick W, Braulke T et al. Organic anion transporters OAT1 and OAT4 mediate the high affinity transport of glutarate derivatives accumulating in patients with glutaric acidurias. Pflugers Arch 2008;457:223–231.
20. Kaufhold M, Schulz K, Breljak D et al. Differential interaction of dicarboxylates with human sodium-dicarboxylate cotransporter 3 and organic anion transporters 1 and 3. Am J Physiol Renal Physiol 2011;301:F1026–F1034.
21. Marenzi G, Lauri G, Assanelli E et al. Serum to urinary sodium concentration ratio is an estimate of plasma renin activity in congestive heart failure. Eur J Heart Fail 2002;4:597–603.
22. Dubbink HJ, Taal W, van Marion R et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 2009;73:1792–1795.
23. Sanson M, Marie Y, Paris S et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009;27:4150–4154.
24. Wick W, Hartmann C, Engel C et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009;27:5874–5880.
25. Weller M, Felsberg J, Hartmann Cetal. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: A prospective translational study of the German Glioma Network. J Clin Oncol 2009;27:5743–5750.
26. Rohle D, Popovici-Muller J, Palaskas N et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013;340:626–630.